Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy

URN to cite this document:: urn:nbn:de:bvb:355-epub-446743
DOI to cite this document:: 10.5283/epub.44674

Scheiter, Alexander ; Keil, Felix ; Lüke, Florian ; Grosse, Jirka ; Verloh, Niklas

; Opitz, Sabine ; Schlosser, Sophie ; Kandulski, Arne ; Pukrop, Tobias ; Dietmaier, Wolfgang ; Evert, Matthias ; Calvisi, Diego F. ; Utpatel, Kirsten

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 16 Mar 2021 14:11

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Fibroblast growth factor receptor 2 (FGFR2) fusions have emerged as a new therapeutic target for cholangiocarcinoma in clinical practice following the United States Food and Drug Administration (FDA) approval of Pemigatinib in May 2020. FGFR2 fusions can result in a ligand-independent constitutive activation of FGFR2 signaling with a downstream activation of multiple pathways, including the ...